Pharmafocus March 2018 is available to read online now!
pharmafile | February 28, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Pharmafocus, brexit, drug safety, pharma, real world data
Though never truly out of vogue, the drug pricing debate has flared up again with the White House’s release of the white paper Reforming Biopharmaceutical Pricing at Home and Abroad. The report asserts that the United States’ healthcare bill – the largest in the world per capita by quite a margin – is due to inefficient regulation and foreign governments which demand universal healthcare and low prices for their citizens, leaving the US to foot the rest of the bill and allow manufacturers to see a return on their investments. You can read the full details on page 7.
All eyes have been on Greece as it emerges that 10 of its politicians, including former Prime Minister Antonis Samaras, stand accused of bribery and collusion with pharma giant Novartis. With the Greek parliament voting in favour of investigating the politicians in question, legal counter-action has been launched and the whole situation threatens to descend into farce. The full story can be found on page 6.
On page 12, we also have exclusive comment from Dr Paul Allen from the University of Roehampton on the remarkable findings unearthed by his institution and King’s College London, whereby schizophrenia patients demonstrated the ability to control auditory verbal hallucinations by using the team’s specially designed video game twinned with an MRI scanner.
Also don’t miss our features on drug safety, real world evidence, and a special head-to-head piece in which Catalyst Corporate Finance’s Tom Cowap and the Brexit Health Alliance’s Sarah Collen put forward their arguments on whether Brexit will be a disaster or big opportunity for the pharma and life sciences industries.
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Novartis acquires Chinook Therapeutics for $3.5bn
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …
